<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664570</url>
  </required_header>
  <id_info>
    <org_study_id>S61853</org_study_id>
    <nct_id>NCT03664570</nct_id>
  </id_info>
  <brief_title>Enteral Nutrition Infusion Rate and Gastric Function</brief_title>
  <acronym>ANTERO-3</acronym>
  <official_title>ANTERO-3: The Impact of Enteral Nutrition Infusion Rate on Gastric Motility and Gastric Emptying Rate, Measured With the VIPUN Balloon Catheter, Magnetic Resonance Imaging and the 13C-octanoate Breath Test.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof Dr Jan Tack</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A complex neurohumoral feedback mechanism regulates gastric emptying of enteral nutrition
      through changes in gastric motility. In this investigation, we aim to investigate the impact
      of different infusion rates of enteral nutrition on gastric motility, gastric emptying rate,
      epigastric symptoms and satiation.

      Additionally, magnetic resonance imaging will be used to validate an extended 13C-octanoate
      breath test for gastric emptying of a liquid test meal that is infused over 2 hours.
      Furthermore, the reliability of a manual position check of the VIPUN Balloon catheter will be
      confirmed with radiographic imaging. Finally, the data will be used for the data driven
      optimization of the VIPUN MI algorithm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Actual">April 5, 2019</completion_date>
  <primary_completion_date type="Actual">April 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motility</measure>
    <time_frame>8 hour</time_frame>
    <description>Motility index (MI) measured with the VIPUN Balloon Catheter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric emptying rate (13C-Octanoate Breath Test)</measure>
    <time_frame>8 hour</time_frame>
    <description>Gastric emptying rate of liquid test meal, measured with 13C-Octanoate Breath Test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric emptying rate (Magnetic resonance imaging)</measure>
    <time_frame>Conditions B and C: 4 hour.</time_frame>
    <description>Gastric emptying rate of liquid test meal, measured with magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiation</measure>
    <time_frame>6 hour</time_frame>
    <description>Subjective satiation score at a 30-minute interval. Visual Analogue Scale (100 mm, 0=absent, 100= maximal sensation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile VIPUN Balloon Catheter</measure>
    <time_frame>Trough study completion, from Visit 1 until completion of Visit 3, on average 3 weeks</time_frame>
    <description>Incidence, frequency, severity, seriousness and relatedness of AE's</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility VIPUN Balloon Catheter related procedures</measure>
    <time_frame>Trough study completion, from Visit 1 until completion of Visit 3, on average 3 weeks</time_frame>
    <description>Success rate of completing the procedure (placement and removal VIPUN Balloon Catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability manual position check</measure>
    <time_frame>Once for each subject (during Condition A only): Position of the inflated balloon is judged on the thorax Rx (t&lt;0) prior to start motility recording (= reference time point, t=0).</time_frame>
    <description>Success rate (pass/fail) (reliability) of the manual position check of the VIPUN balloon catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Position catheter at t=480.</measure>
    <time_frame>During Condition A only: at t=480 minutes (after cessation motility recording).</time_frame>
    <description>Qualitative assessment of the migration of the catheter over the course of the study procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigastric symptoms</measure>
    <time_frame>6 hours</time_frame>
    <description>Subjective epigastric symptom scores at a 30-minute interval. 3 Visual Analogue Scales (100 mm, 0=absent, 100= maximal sensation). Scale 1: Nausea, Scale 2: Bloating, Scale 3: Pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Condition A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion rate = 25 ml/h
Radiography: confirmation balloon position
VIPUN Balloon Catheter
13C-Octanoate Breath Test o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Condition B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion rate = 75 ml/h
Magnetic resonance imaging
VIPUN Balloon Catheter
13C-Octanoate Breath Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Condition C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion rate = 250 ml/h
Magnetic resonance imaging
VIPUN Balloon Catheter
13C-Octanoate Breath Testt</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIPUN Balloon Catheter</intervention_name>
    <description>The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.</description>
    <arm_group_label>Condition A</arm_group_label>
    <arm_group_label>Condition B</arm_group_label>
    <arm_group_label>Condition C</arm_group_label>
    <other_name>VIPUN system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  At least 18 years old

          -  BMI between and including 18 and 30

          -  Understand and able to read Dutch

          -  In good health on the basis of medical history

          -  Female subjects of childbearing potential are willing to use adequate contraception

          -  Refrains from herbal, vitamin and other dietary supplements on the day of the visits

        Exclusion Criteria:

          -  Dyspeptic symptoms (assessed with PAGI-SYM questionnaire)

          -  Using any medication that might affect gastric function or visceral sensitivity

          -  Known / suspected current use of illicit drugs

          -  Known psychiatric or neurological illness

          -  Any gastrointestinal surgery that could influence normal gastric function in the
             opinion of the investigator

          -  History of heart or vascular diseases like irregular heartbeats, angina or heart
             attack

          -  Nasopharyngeal surgery in the last 30 days

          -  History of thermal or chemical injury to upper respiratory tract or esophagus

          -  Current esophageal or nasopharyngeal obstruction

          -  Known coagulopathy

          -  Known esophageal varices

          -  Metal or other MRI incompatible implants

          -  Contra-indications for MR (checked by MR safety questionnaire)

          -  Pregnancy

          -  Claustrophobia

          -  Have a known allergy or intolerance to cow milk, soy, saccharose or any other
             ingredient of Isosource Standard.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Jan Tack</investigator_full_name>
    <investigator_title>Head of Clinic - Gastroenterology / Professor of Medicine / Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastric motility</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

